Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

This article does not contain an abstract and presents no new clinical findings, instead discussing prior cases and literature on infant alopecia universalis and the potential role of topical PUVA therapy.

This report describes a neurometabolic disorder linked to gain-of-function variants in the ODC1 gene, characterized by developmental delay, ectodermal abnormalities, and notable facial and neuroimaging features.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This study reported that a shampoo containing alcoholic extract of Urtica urens L. was effective in reducing hair loss by over 50% without causing skin irritability.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

This study found that TPA treatment transiently induces high levels of ODC in mouse epidermal cells, particularly around hair follicles, with localization reduced by retinoic acid or cycloheximide pretreatment.

This study found that the hydroalcoholic extract of Urtica dioica L. demonstrated some clinical efficacy in reducing lesion severity in guinea pigs with Microsporum canis infections, suggesting potential as a supplementary topical treatment for tinea corporis.

This study found that a shampoo containing 2% alcohol extract of Urtica urens L. reduced hair loss by 56.8% in individuals with non-pathological hair loss after 21 days.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This study found that Urticadioica L ethanol extracts enhanced hair growth and reduced catagen transition in human hair follicles in an ex vivo organ culture model.

This study found that early treatment of alopecia areata with JAK inhibitors can improve patients' physical and psychological quality of life without worsening skin lesions associated with sarcoidosis.

In this study, researchers found that the histone demethylase UTX is crucial for regulating skin differentiation through retinoic acid signaling, mainly impacting females, as males compensate with a Y-linked paralog.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This study found that US adults with classic congenital adrenal hyperplasia most preferred a hypothetical adjunctive therapy that prevents glucocorticoid-induced weight gain over other potential benefits.

Farudodstat may effectively treat alopecia areata without harmful side effects.

This abstract describes the initial success of intralesional cidofovir for SCC treatment and states that it has not shown systemic toxicity, but it does not report new clinical trial results.

This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

This case report found that a 48-year-old woman with idiopathic twenty-nail dystrophy experienced significant improvement in nail appearance after six months of treatment with oral Upadacitinib.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.